“That being said, the right PR company (who handles biotech companies) would know how to craft a PR that doesn't market the product.”

My mind continues to be blown by the poorly written PRs, which we’ve talked about at length here. What blows my mind more is the fact that we have the funds to pay for advertisements, such as Proactiv and the stock web conferences, but can’t pony up the cash to pay a legit PR firm to write PRs, which I would argue are the MOST important items to come from a biotech.